Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s own Tecfidera (dimethyl fumarate) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
The Phase 3 study sought to determine the gastrointestinal tolerability, including duration and severity, of diroximel fumarate 462mg twice daily compared to Tecfidera 240mg twice daily, with a primary endpoint measuring the intensity and number of days that gastrointestinal symptoms were experienced.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
